JAK1 and congenital rubella syndrome: Corticosteroids, tocilizumab anakinra in CRS associated neurotoxicity ruxolitinib a JAK1/JAK2 inhibitor. Genetic manipulation of CAR T-cells engineered to express and secrete IL-1RA